Vyalev’s clearance is the second victory for AbbVie in Parkinson’s this year, following an April readout for a drug acquired through its Cerevel buyout.

The deal offers Lexicon a cash infusion of $25 million as the company tries to broaden use of the heart failure and diabetes medication.

Precis Engineering + Architecture , an award-winning design firm with locations in Ambler, PA, and Cary, NC, has hired Veera ...

The results provide the first clinical evidence of RNA editing, a burgeoning field that's drawn interest from biotechs and pharmaceutical companies alike.

The hold, which was made in response to a serious adverse event report, could impact the company’s plans to start a Phase 3 trial of a combination shot for COVID-19 and influenza.

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.

The pharma will work with Triana Biomedicines on molecular glue degraders. Elsewhere, Akeso raised $250 million and a MASH drug developer got a well-known board chair.

The lawsuit focuses on scientific work that helped clear the path for creating mRNA vaccines to fight the COVID-19 pandemic.

To enhance patient outcomes and increased trial success, Convert Pharma is leveraging companion AI- and genetic biomarkers, a ...

Harris aims to broaden some IRA provisions, including Medicare drug price negotiation, while Trump has adopted a more industry-friendly approach.

Alimentiv, a full-service GI CRO and pioneer in IBD medical imaging solutions since 1986, is excited to announce the expansion of its partnership with Satisfai Health, a leader in AI medical solutions ...

The French pharmaceutical giant said it’s in negotiations to sell a controlling stake of Opella to the private equity firm CD&R, in a deal that reportedly could be worth more than $16 billion.